Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogenic yeast in the urogenital tract refers primarily to infection by Candida species, a genus of opportunistic fungi that are part of the normal human microbiota but can cause disease (candidiasis) when host defenses are compromised. The most common species, Candida albicans, along with others such as C. glabrata, C. tropicalis, C. parapsilosis, and C. krusei, can cause vaginitis, balanitis, and, more rarely, urinary tract infections. Diagnosis is based on symptoms, microscopy, and laboratory identification of Candida. Treatments include topical or systemic antifungal agents. Drug resistance, recurrence, and complications may occur, particularly in at-risk populations such as diabetics, pregnant women, and immunocompromised patients.
Inhibition of fungal cell membrane synthesis (azole and polyene classes); Inhibition of β-(1,3)-D-glucan synthesis in fungal cell wall (echinocandins)
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Candida species (pathogenic yeast).